吉非替尼联合洛铂胸腔内灌注治疗肺癌恶性胸水临床疗效及生活质量分析  

Clinical Efficacy and Quality of Life Analysis of Intrapleural Perfusion of Gefitinib and Loplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer

作　　者：董建春[1] 郭春辉[1] 韩贞[1] 尹彦海 赵吉庆[1] 张继宝[1] DONG Jian-chun;GUO Chun-hui;HAN Zhen;YIN Yan-hai;ZHAO Ji-qing;ZHANG Ji-bao(Department of Respiratory Medicine,Binzhou Central Hospital,Binzhou,Shandong Province,251700 China)

机构地区：[1]滨州市中心医院呼吸内科,山东滨州251700

出　　处：《系统医学》2020年第17期4-6,共3页Systems Medicine

摘　　要：目的肺癌并恶性胸水应用吉非替尼与洛铂胸腔内灌注联合治疗效果情况分析。方法选取2018年11月—2019年11月该院诊治78例肺癌并恶性胸水患者资料,随机分为两组,对照组予洛铂胸腔内灌注,研究组予吉非替尼与洛铂胸腔内灌注联合治疗,分析两组临床疗效、不良反应与生活质量情况。结果治疗后,研究组临床有效率74.36%比对照组51.28%高(χ^2=4.446,P<0.05);研究组腹泻51.28%、皮疹56.41%等不良反应比对照组38.46%、41.03%多,但差异无统计学意义(P>0.05);且研究组生理机能(75.51±5.23)分、精力(76.18±5.16)分、躯体疼痛(75.19±5.46)分与社会功能(74.03±5.26)分,均高于对照组,差异有统计学意义(t=7.908、9.360、8.957、7.479,P<0.05,)。结论肺癌并恶性胸水应用吉非替尼与洛铂胸腔内灌注联合治疗,能有效提高疗效,提高患者生活质量,具一定临床应用价值。Objective To analyze the effect of combined treatment of gefitinib and lobaplatin in the treatment of lung cancer with malignant pleural effusion.Methods The data of 78 patients with lung cancer and malignant pleural effusion diagnosed and treated in the hospital from November 2018 to November 2019 were randomly divided into two groups.The control group received intrapleural perfusion of lobaplatin,and the study group received intrapleural infusion of lobaplatin and gefitinib combined perfusion therapy,the clinical efficacy rate,adverse reactions and quality of life of the two groups were analyzed.Results After treatment,the clinically effective rate 74.36%of the study group was higher than that of the control group 51.28%(χ^2=4.446,P<0.05);the study group had more adverse reactions such as 51.28%of diarrhea and 56.41%of the rash than the control group,38.46%and 41.03%,but there was no statistical significance difference(P>0.05);and the scores of physiological function(75.51±5.23)points,energy(76.18±5.16)points,physical pain(75.19±5.46)points and social function(74.03±5.26)points of the study group were higher than the control group,the difference was statistically significant(t=7.908,9.360,8.957,7.479,P<0.05).Conclusion Intrapleural perfusion of gefitinib and lobaplatin in lung cancer complicated with malignant pleural effusion can effectively improve the curative effect and improve the quality of life of patients,and has certain clinical application value.

关 键 词：吉非替尼 洛铂 胸腔内灌注 肺癌 恶性胸水 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]